Losartan Potassium and Hydrochlorothiazide Recall: Impurity Levels Above Acceptable Limits
Direct Rx is recalling Losartan Potassium and Hydrochlorothiazide tablets due to azido impurity levels above acceptable limits resulting from manufacturing deviations. Patients should consult their healthcare provider regarding their medication.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving impurity levels above acceptable limits in a prescription drug due to CGMP deviations. No illnesses or injuries are reported in the source material, making this a theoretical risk rather than proven harm. Per the severity rubric, when no illnesses are reported and the hazard is theoretical, the maximum score is 3 (High).
Plain-English summary
Direct Rx is recalling 11 bottles of Losartan Potassium and Hydrochlorothiazide (100/12.5 mg, 90 tablets per bottle) due to Current Good Manufacturing Practice (CGMP) deviations. The recalled medication has lot number 25OC2116 with an expiration date of May 31, 2023, and was distributed in Florida.
The recall was initiated because azido impurity levels in the affected bottles were observed to be above acceptable limits. This represents a manufacturing quality issue identified during product oversight.
If you have this medication, do not use it. Consult your healthcare provider or pharmacist immediately to discuss your treatment options and obtain appropriate replacement medication.
The recalled product
- Product
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)
- Brand
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Direct Rx
- Affected units
- 11
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 25OC2116 Exp. 5/31/23
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 3 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- HighLosartan Potassium and Hydrochlorothiazide Tablets Recalled for Foreign Plastic Contamination
FDA (Drugs) · 2024-05-22
- HighFDA Recalls Losartan-Hydrochlorothiazide Tablets for Manufacturing Quality Deviations
FDA (Drugs) · 2022-07-06
- HighBlood Pressure Medication Losartan-HCTZ Recalled for Impurity Deviation
FDA (Drugs) · 2022-06-08
- HighBlood Pressure Medication Recalled for Manufacturing Impurity
FDA (Drugs) · 2022-06-01
- HighBlood pressure medication Losartan and hydrochlorothiazide recalled for elevated azido impurity
FDA (Drugs) · 2022-06-01
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · azido impurity
See all →- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Manufacturing Impurity Issues
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium tablets recalled for elevated AZIDO impurity
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for CGMP Deviations and Elevated Impurity
FDA (Drugs) · 2022-06-08
- HighLosartan HCTZ drug recall due to azido impurity levels above limits
FDA (Drugs) · 2022-06-01